|1.||Bohlen, Peter: 3 articles (07/2005 - 05/2002)|
|2.||Scheinberg, David A: 2 articles (11/2010 - 01/2010)|
|3.||Villa, Carlos H: 2 articles (11/2010 - 01/2010)|
|4.||McDevitt, Michael R: 2 articles (11/2010 - 01/2010)|
|5.||May, Chad: 2 articles (01/2010 - 07/2005)|
|6.||Liao, Fang: 2 articles (03/2005 - 05/2002)|
|7.||Escorcia, Freddy E: 1 article (11/2010)|
|8.||Smith-Jones, Peter: 1 article (11/2010)|
|9.||Blasberg, Ronald G: 1 article (11/2010)|
|10.||Benezra, Robert: 1 article (11/2010)|
03/01/2005 - "In tumor models and in vivo and in vitro assays, the anti-VE-C antibody E4G10 has been shown to specifically inhibit angiogenesis, but VE-C has yet to be inhibited in the context of ovarian angiogenesis. "
01/01/2010 - "The E4G10 antibody specifically targeted the monomeric vascular endothelial-cadherin (VE-cad) epitope expressed in the tumor angiogenic vessels. "
07/01/2005 - "The anti-VE-cadherin monoclonal antibody E4G10 was a weaker inhibitor of tumor angiogenesis and growth than DC101, and also caused a weaker increase in tumor cell invasion. "
11/15/2010 - "By selectively killing tumor neovasculature using short-ranged α-particles targeted to vascular endothelial (VE)-cadherin on vascular endothelial cells (by use of 225Ac-labeled E4G10 antibody) we were able both to reduce tumor growth and to increase the efficacy of chemotherapy, an effect seen only when the chemotherapy was administered several days after the vascular targeting agent, but not if the order of administration was reversed. "
01/01/2010 - "Single wall carbon nanotube (SWCNT) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] or desferrioxamine B [DFO]) and the tumor neovascular-targeting antibody E4G10. "
|2.||Carbon Nanotubes (Carbon Nanotube)
|1.||Drug Therapy (Chemotherapy)